Spark Ther­a­peu­tics faces a grilling as FDA pon­ders a pi­o­neer­ing OK for gene ther­a­py

With one of the most close­ly-watched FDA pan­el re­views of the year com­ing up for Spark Ther­a­peu­tics’ $ONCE lead gene ther­a­py, in­ter­nal re­view­ers at the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA